Imatinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Imatinib, also known as Gleevec ([[____]])"/> ===Better Known as: Gleevec=== * Marketed By: ... |
David Canner (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Imatinib, also known as Gleevec ([[____]])"/> | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Imatinib, also known as Gleevec ([[____]])"/> | ||
===Better Known as: Gleevec=== | ===Better Known as: Gleevec=== | ||
* Marketed By: | * Marketed By: Novartis | ||
* Major Indication: | * Major Indication: Leukemia and Gastrointestinal Stromal [[Cancer|Tumors]] | ||
* Drug Class: | * Drug Class: Receptor Tyrosine Kinase (Especially PDGFR & KIT) Inhibitor | ||
* Date of FDA Approval (Expiration): | * Date of FDA Approval (Expiration): 2001, (2015) | ||
* 2009 Sales | * 2009 Global Sales: $3.9 Billion | ||
* Importance: | * Importance: | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | ||
